Fractyl Health, Inc. (GUTS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on June 4, 2026, by Fractyl Health, Inc., a Delaware corporation. The report discloses positive one-year results from the open-label REVEAL-1 Cohort study regarding the Company's Revita procedure. The study focuses on individuals with obesity who had lost at least 15% of their total body weight on GLP-1 medications and subsequently discontinued therapy.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. This report is a regulatory disclosure of clinical trial results and does not contain a financial statement or earnings update.
Material Changes and Clinical Results
The primary material event is the announcement of clinical efficacy data for the Revita procedure:
- Weight Maintenance: Patients maintained approximately 78% of their prior GLP-1-induced weight loss at one year post-procedure.
- Continued Weight Loss: 33% of participants continued to lose weight one year after discontinuing GLP-1 therapy.
- Weight Change: Mean total body weight change was 5.3% (n=15) and 5.8% (n=22) at one year.
- Responder Rate: 100% of patients maintained at least 5% of GLP-1-induced weight loss, meeting the responder definition used in the REMAIN-1 Pivotal Cohort.
- Metabolic Impact: Minimal change in HbA1c levels (0.08%) was observed, compared to a ~0.4% increase seen in historical controls post-GLP-1 discontinuation.
- Safety: No procedure-related serious adverse events were observed. Mild adverse events occurred in 36% of participants, were transient, and occurred within the first month.
Outlook, Risks, and Management Commentary
Management highlighted the durability of the Revita procedure for weight maintenance after GLP-1 discontinuation. The data supports the second co-primary endpoint of the REMAIN-1 Pivotal Cohort. The filing notes that the information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability exposure for the forward-looking statements contained in the press release.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed statistical analysis and study limitations.
- Confirm the enrollment criteria and baseline characteristics of the 22 participants in the REVEAL-1 Cohort.
- Review the design and timeline of the REMAIN-1 Pivotal Cohort to understand the path to regulatory approval.
- Assess the commercial implications of the Revita procedure as a weight maintenance solution in the context of the GLP-1 market.
- Check for any subsequent filings regarding the financial impact of these clinical results on the Company's cash burn or funding needs.